Clinical trials: Prostate Cancer Detection
Prostate Cancer, Prostate Cancer Recurrent
F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence
This study evaluates the diagnostic performance and safety of F-18-PSMA-1007 and F-18-Fluorocholine PET/CT imaging in patients with suspected recurrence of prostate cancer after previous definitive treatment.
- Trial name
- NCT04102553
- Testing
- F-18-PSMA-1007, F-18-Fluorocholine
- Where
- 6 sites in France
- Volunteers
- 200 people
- Sponsor
- ABX advanced biochemical compounds GmbH
Prostatic Neoplasm
Determination of the Diagnostic Detection Rate of Axumin (Fluciclovine) Digital PET/CT, Post-prostatectomy
Fluciclovine F18 (Axumin) has been demonstrated to provide good delineation of recurrence of prostate cancer after definitive therapies.
- Trial name
- NCT04234399
- Testing
- Fluciclovine PET/CT using a digital PET/CT
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Vermont
Prostate Cancer, Urologic Cancer
The Man Van Project
National Health Service (NHS) England has commissioned The Royal Marsden Hospital NHS Foundation Trust to run a novel mobile clinical outreach service called 'Man Van' with the aim of enabling male patients' easy access to care…
- Conditions
- Prostate Cancer, Urologic Cancer, Urologic Diseases, Bladder Cancer
- Trial name
- MV (NCT06357416)
- Testing
- MV-POCT Sub-study, Main Man Van Group Sub-study (MV-Eco), MV-QualQ Sub-study
- Where
- United Kingdom
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Prostate Cancer
Transrectal Ultrasound Robot-Assisted Prostate Biopsy
Prostate cancer (PCa) is the most common non-dermatologic malignancy in U.S. men. Transrectal ultrasound (TRUS)-guided prostate biopsy is a commonly used diagnostic procedure for men with an elevated serum prostate-specific…
- Trial name
- NCT02871726
- Testing
- TRUS-Robot, TRUS biopsy
- Where
- United States
- Volunteers
- 483 people
- Sponsor
- Johns Hopkins University
Prostate Cancer, Neoplasm, Residual
Feasibility of the LUM Imaging System for Detection of Prostate Cancer
The primary objective of this feasibility study is to determine if administration of LUM015 will result in positive fluorescence of tumor tissue from ex vivo specimen imaging with the LUM Imaging device from patients undergoing…
- Trial name
- NCT03441464
- Testing
- LUM Imaging System
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Lumicell, Inc.
Metastatic Castrate Resistant Prostate Cancer
Detection of ARv7 in the Plasma of Men With Advanced Metastatic Castrate Resistant Prostate Cancer (MCRP)
Demonstrate detection of ARv7 splice variant transcripts from exosomes in the circulation of MCRPC patients pre and post treatment with selective Androgen pathway inhibitors (i.e. abiraterone and enzalutamide)
- Trial name
- NCT03236688
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Exosome Diagnostics, Inc.
Prostate Cancer, Active Surveillance for Prostate Cancer
Micro-Ultrasound for Detecting Clinically Significant Prostate Cancer in Active Surveillance
Active surveillance is a common approach for men with low-risk or favorable intermediate-risk prostate cancer, aimed at avoiding or delaying treatment while closely monitoring the disease.
- Conditions
- Prostate Cancer, Active Surveillance for Prostate Cancer, Imaging Techniques
- Trial name
- MUS-AS (NCT07386171)
- Testing
- Micro-Ultrasound (mUS)
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Prostate Cancer
Al18F-PSMA-617 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients
18F-labeled prostate-specific membrane antigen (PSMA) ligand-positron emission tomography (PET) offers advantages over 68Ga-labeled PSMA ligands. Al18F-PSMA-617 is a novel 18F-PSMA compound used for prostate cancer (PCa) imaging.
- Trial name
- NCT05841992
- Testing
- Al18F-PSMA-617, 68Ga-PSMA-617
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Prostate Carcinoma
Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial
This clinical trial tests how well a urine prostate cancer screening test, My Prostate Score 2 (MPS2), integrated with magnetic resonance imaging (MRI) works for early detection of prostate cancer.
- Trial name
- UPRISE (NCT07526545)
- Testing
- Biopsy Procedure, Diagnostic Procedure, Electronic Health Record Review
- Where
- United States
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- University of Michigan Rogel Cancer Center
Prostate Cancer, Prostate Adenocarcinoma
Prospective Comparison of the Four Biopsy Methods for Prostate Cancer Detection
The aim of this study is to compare clinically significant prostate cancer detection rate by the 4 biopsy methods: TRUS-guided, cognitive, fusion and transperineal template mapping biopsy.
- Trial name
- NCT05589558
- Testing
- consequently performed 4 biopsy methods (TRUS-guided biopsy, cognitive, fusion and transperineal template mapping biopsy)
- Where
- Russia
- Volunteers
- 102 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Prostate Cancer
Imaging Guided Surgery to Improve the Detection of Lymph Node Metastases in Prostate Cancer Patients
The project aims at assessing the role of radio-guided surgery in the detection of lymph node invasion (LNI) in prostate cancer (PCa) patients undergoing radical prostatectomy (RP) by using an intraoperative gamma probe and a…
- Trial name
- NCT04832958
- Testing
- 99m-TC-PSMA-I&S
- Where
- Italy
- Volunteers
- 81 people
- Sponsor
- IRCCS San Raffaele
Prostate Neoplasm
Unfavorable MRI But Favorable 68Ga-PSMA PET/MRI for Primary Prostate Cancer Detection
This perspective cohort study aims to assess the detection rate of prostate cancer through prostate biopsy within suspicious patients harboring unfavorable multiparametric MRI but favorable 68Ga-PSMA PET/MRI who have had no prior…
- Trial name
- NCT04124107
- Testing
- multiparametric MRI and 68Ga-PSMA PET/MRI, Prostate biopsy
- Volunteers
- 50 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prostate Cancer
Multicentric Evaluation of the True Negative Predictive Value of Multiparametric MRI for the Detection of Prostate Cancer Using Cystoprostatectomy Specimen as Reference
To evaluate the negative predictive value of mpMRI in the detection of prostate cancer using cystoprostatectomy specimen as the reference
- Trial name
- NPV-MRI-02 (NCT03960112)
- Testing
- mpMRI
- Where
- 5 sites in France
- Volunteers
- 12 people
- Sponsor
- Institut Paoli-Calmettes
Prostate Cancer
Non-contrast MR Imaging for Whole Body Cancer Detection and Characterization
This study aims to learn how to improve MRIs (Magnetic Resonance Imaging) that do not require the patient to be injected with a contrast dye.
- Trial name
- NCT03440554
- Testing
- Whole Body Non-Contrast MRI
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of California, San Diego
Biochemical Relapse Fo Malignant Neoplasm of Prostate
18F-FACBC PET/CT and the PSA Kinetics for PCa Patients With Biochemical Recurrence.
Prostate cancer (PCa) is the fifth-most common cancer for male with a seventh highest cancer-related death in Taiwan. Currently, the incidence and mortality rate are still increasing rapidly.
- Trial name
- NCT05048537
- Testing
- 18F-FACBC PET/CT
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
Prostate Cancer
Prostate HistoScanning for the Non-invasive Detection and Staging of Prostate Cancer and Characterization of Prostate Tissues (PHS-02)
Study design: -The study will be a phase I like study to assess the extent to which prostate HistoScanning (PHS, the index test) can identify and characterize foci of prostate cancer when compared to histological samples…
- Trial name
- PHS-02 (NCT01191931)
- Where
- 7 sites in Belgium, Czechia and 3 more
- Volunteers
- 52 people
- Sponsor
- Advanced Medical Diagnostics s.a.
the Detection of Prostate Cancer in Men
Early Detection of Prostate Cancer of Syrian Men
Prostate cancer is a significant health concern in the Middle East, including Syria, where many cases are diagnosed at advanced stages due to low awareness and inadequate screening practices.
- Trial name
- NCT07075666
- Testing
- PSA, DRE
- Where
- Syria
- Volunteers
- 1,000 people
- Sponsor
- Al-Hawash Private University
Prostate Cancer
Prostasomes as Diagnostic Tool for Prostate Cancer Detection
Prostate cancer is the most frequently diagnosed cancer among men over 50 years old in Western societies, with an incidence that is steadily increasing in most countries.
- Trial name
- NCT03694483
- Testing
- Genetic analysis for the detection of prostasomes
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Hackensack Meridian Health
Suspected Primary Prostate Cancer
Evaluation of a Transrectal Scintigraphic Detector(ProxiScanTM) for Detection of Primary Prostate Cancer
This is a feasibility, exploratory, and proof-of-concept study to evaluate rectal probe scintigraphy device (ProxiScanTM) to detect PSMA specific radiopharmaceutical agent (ProstaScint®) in patients with suspected primary…
- Trial name
- NCT01359189
- Testing
- ProxiScan (scintigraphic rectal probe)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
UCI 03-72 Prostate Cancer Detection by Serum Proteomic Profiling
: Researchers would like to see if a new test called SELDI (Surface Enhanced Laser Desorption Ionization) analysis can predict biopsy results better than PSA tests.
- Trial name
- NCT00355758
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of California, Irvine